OR WAIT null SECS
The new facility is solely dedicated to offer extractables and leachables (E&L) testing services to the pharmaceutical and related industries.
Bio/pharmaceutical analytical and bioanalytical contract solutions provider, SGS, has opened a new facility in Wiesbaden, Germany. The 500-m2 facility will be solely dedicated to offer extractables and leachables (E&L) testing to the pharmaceutical and related industries.
Previously, E&L testing was done at the company’s laboratory in Taunusstein, Germany, approximately 20 km from the new facility. But due to increasing customer demand, SGS decided to invest in a new facility, which will exclusively cater for E&L testing.
Equipment and instruments from Taunusstein, as well as newly acquired machines, have been qualified and validated at the new Wiesbaden laboratory. Ongoing projects have also been successfully transferred to Wiesbaden. SGS says that the space vacated at Taunusstein will be used to expand its quality control release testing capabilities.
SGS aims to make the new facility in Wiesbaden a center of excellence for extractable studies and impurities profiling across its global network of laboratories. The company has 21 laboratories in North America, Europe, and Asia, offering contract analytical and bioanalytical services to the pharmaceutical and biotech industry. SGS also provides Phase I to IV clinical trial management, and services encompassing data management and statistics, pharmacokinetic/pharmacodynamic modeling and simulation, pharmacovigilance, and regulatory consultancy.